An observational study in Glaucoma, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 40 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Oregon Health and Science University · Observational
Among 490 studies in Glaucoma with a site in United States — 77 open to participants now, 96 under way, 5 of them phase 3. Glaucoma · United States.
Among the 490 studies in Glaucoma with a site in United States, this one is the 18th largest by planned enrollment of the 110 observational ones, is one of 23 that started in 2013, is one of 110 observational ones, reaches primary completion later than 92 of the 95 other live ones, and was the 210th registered.
1,419 studies on the registry are indexed under Glaucoma; 223 are open to participants now.
This study's planned enrollment of 249 is above the median of 101 across 385 observational studies indexed under Glaucoma.
Browse Glaucoma studies →77 of the 490 studies in Glaucoma with a site in United States are open now, in 5 countries. Each count lists the studies.
Of the 156 Glaucoma studies recruiting now, 114 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 45 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →490 studies; the count open now beside each. This study's row is marked.
First in 1976; this study’s year is marked. 23 started in 2013.
Median enrollment 79 across the 364 interventional studies, 100 across the 110 observational. Of the 356 that completed or were terminated, 138 (39%) have results posted.
210 of 490 have an industry lead sponsor. The 10 most frequent:
Oregon Health and Science University is the lead sponsor of 696 studies on the registry; 131 are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 39 (75%) have results posted.
Oregon Health and Science University has 6 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
35 of the studies in Glaucoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04967989Phase 3University of PittsburghClarifying the Optimal Application of SLT Therapy Trial | 2027-06-30 |
| NCT07510087Marc Toeteberg-HarmsGlaucoma Related Quality of Life | 2026-11-30 |
| NCT05626426Stanford UniversityElectrical Stimulation for the Treatment of Optic Neuropathies | 2026-12 |
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT06615661Iantrek, Inc.A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma | 2026-12 |
Among the 490 studies in Glaucoma with a site in United States, from their registry updates:
The specific aims of the clinical studies are to:
Glaucoma is the second leading cause of blindness in the US. The diagnosis and monitoring of glaucoma are important problems, not only because of its prevalence, but also because of its silent and irreversible nature. However all of the current diagnostic tests have serious limitations. Although elevated intraocular pressure (IOP) is a risk factor, most glaucoma patients actually have IOP within normal range. Visual field (VF) tests are poorly reproducible, and a series of 3 tests are needed to establish diagnosis or confirm progression. Although ophthalmoscopic examination can detect optic nerve head (ONH) and nerve fiber layer (NFL) defects, reliability in diagnosis and tracking is hampered by its subjective and semi-quantitative nature. Although quantitative imaging with optical coherence tomography (OCT), scanning laser polarimetry (SLP), and confocal scanning laser ophthalmoscopy (cSLO) can more objectively detect ONH and NFL defects, their diagnostic accuracies are still not sufficient to be relied on alone for diagnostic screening. It has been estimated that about half of glaucoma patients in the US do not know that they have the disease. Thus, there is a need for improvements in glaucoma diagnostic technologies. One approach that deserves further exploration is blood flow imaging.
There is much circumstantial evidence that vascular factors play important roles in the pathophysiology of glaucoma:
Despite the evidence, the management of glaucoma remains focused on the lowering of IOP, the one causative factor that responds to treatment and can be easily measured. Blood flow measurement is a research topic, but currently has no clinical role in the diagnosis, prognostic evaluation, or treatment of glaucoma. Therapies aimed at improving ocular circulation cannot be effectively developed without a practical method for quantitative and reproducible evaluation of ONH and retinal perfusion. Thus there is a great need to develop better technology for the evaluation of ocular circulation.
Using high-speed OCT systems, we have developed new methods to image and measure optic nerve head (ONH) and retinal blood flow. Preliminary results showed that VF loss was more highly correlated with retinal blood flow as measured by OCT than any neural structure measured by OCT or other imaging modality. Accordingly, the goal of the proposed project is to improve the diagnostic and prognostic evaluation of glaucoma by further developing novel functional OCT measurements using ultrahigh-speed (70-100 kHz) OCT technology.
Retinal blood flow, ONH circulation, optic disc rim volume, peripapillary nerve fiber layer volume, and macular ganglion cell complex volume are all pieces of the same glaucoma puzzle. This project will develop novel imaging methods that allow us to look at the whole picture using one tool - ultrahigh-speed OCT.
The study will enroll both males and females and include all ethnic and racial groups through clinical practices in the centers. The study will enroll subjects in the older adult age range commonly affected by glaucoma - 40 years or older. The study will exclude people with life-threatening or debilitating illness that would make 5-year participation unlikely or cooperation with tests difficult. For similar reasons those older than 85 years are excluded. The study also excludes those with any disease that might confound the diagnosis of glaucoma. Otherwise people with any health status are eligible for enrollment. Two groups of participants are recruited in the study: healthy controls or participants with confirmed glaucoma.
Inclusion Criteria: Normal Subjects (both eyes must meet all criteria)
Inclusion criteria: Glaucoma Group
ONH or NFL defect visible on slit-lamp biomicroscopy defined as one of following:
Exclusion Criteria: All Groups
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with clinically confirmed glaucomatous ONH or NFL defects, with or without VF abnormalities
Volunteers with healthy eyes
Measure of retinal non-perfusion areas in mm2
Time frame: 5 years
Measure vessel density in percentage (%)
Time frame: 5 years
Determine accuracy of sector visual field progression in OCT-based sector visual field simulation compared to actual visual field results. Measured in dB change over time.
Time frame: 5 years
Started Sep 2013 (actual). Primary completion is estimated for May 2031, 212 months after the start.
Of 110 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 212 months is above that.
Counting every sponsor, half of 134 studies reached it within 31 months; a quarter within 12 and three quarters within 208.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oregon Health and Science University →